Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Having built a substantial holding in Synairgen, this is the month I have been waiting for. The MM games, the distressed sellers, the traders, the headlines... Even a feature on Panorama!
So this month we will see if 15 years development has paid off. I have taken into account SNG published papers, numerous research papers on Interferon Beta and also the recently published papers and trials on Interferon use against C-19.
Ultimately Aim is a corrupt place where MM’s can do what ever they choose. Trying to ignore their games is tough. Trying to ignore the trolls and negativity on here and elsewhere can be tough, as seeds of doubt are planted.
However ultimately, I believe in the drug, I believe in the outstanding Professors involved in this project and I believe in Richard Marsden.
Good luck all holders here. The next 21 days will be an fun and hopefully transformative journey!
Totally agree. The science speaks for itself. A key thing for me is the trial expansion, if it wasn't for that, I feel this would have been a complete gamble. You simply never increase a trials recruitment criteria, especially to less sick patients if firstly, the drug isnt safe and secondly if efficacy signals are being shown (from a financial and more importantly, ethical point of view). On top of that, they even expanded recruitment for the "less sick" cohort of patients who are receiving treatment at home. This was the game changer for me hence why I expect positive results for the primary endpoints. With a positive RNS, I don't expect this to rocket to 1 pound like some here think it will, but to the 60-70p mark. Following a positive trial, I expect speedy marketing authorisation and a potential big pharma company stepping in to help produce and distribute.
There may be 21 trading days in July but there's nothing to stop COPD data landing tomorrow. Even the COVID hospital data could well come before the very end of the month. Neither are set in stone for any date and just guesstimates.
We should have the COvid results on the 20th or the 21th imo
COPD results should have been in June but we are still waiting ....
Not sure playing a guessing game helps. We were not told June for COPD. We’ve been told end of July for COVID but I agree potentially could fall from around the 20th. Other than that news will come when it’s ready. Not long now considering how long we have waited thus far.
correct me if I am wrong, were we not just told "July" rather than end of July...
Yes I agree COPD results are due any day.
RM did say that had allot of data from this tests as samples were taken in the research hospital labs. So plenty to analyse !
It was also interesting that the COPD results will cover multiple viral infections...
RM said Summer for COPD and July C-19.
So left it wide open !
Well the most recent confirmation I think was RM in his recent interview where he said hospital data in july and I’m sure he said this time next month or a few weeks.
SS ,
Can't see what you mean because the interim analysis is a Statisical analysis and so I cannot see what ´samples ´ you are talking about ??
Evgen Pharma held a double blind P2 trial at the same venue, it was larger than SNG trial. All the the dataset was analysed and verified in 3wks (with loads of data) I've know doubt SNG knows the outcome of the COPD results, I believe that the COPD dataset is going to be used to assist the Covid-19 hospital trial, therefore released at same time would be highly likely.
Bebeto ,
That is where I see the problem ...
If the COPD results are conclusive , why not publish them straight away ?
If they publish both sets of results a report the same time , that would mean to me that the results are Not very conclusive ...
RM confirmed that they have to release the data when they receive it. They can’t hang onto it.
They will either say “we want all data together” or they will separate it. They will not see one set and then hold onto it for the other set.
Timing of results release could also be influenced by some kind of corporate deal event - so a combination of price sensitive factors that may indeed require some managed co-ordination
I Carnt see why SNG should hold onto any info. If they have the COPD data they need to release it to the markets ASAP.
Jakman,
What could be the ´ price sensitive factors ´ ?
Nolupus - let me use an analogy. I’m a property developer and I acquire a large piece of land pre planning. Whilst I go through the process of getting permission (plans and working with local development team - likely to take me 12-18 mths) I have lined up 2 national builders to acquire the site with PP and have agreed term sheets etc and allowed them due diligence which includes all the survey results / draft plans etc in order to negotiate the land value for the deal. As soon as PP granted the sale transaction completes
meanwhile, Blife is launching clinical trials of AP-003 ( inhalation of INFa2b ).
again using method of direct delivery of interferon to lungs.
their diagram explains early intervention nicely
https://blifetherapeutics.com/
Worth a watch if you haven’t seen it. I hadn’t but found the Q&A session at the end informative. Also Supports view this is not just a Covid play. RM just before the halfway point goes through values of some drugs at phase I, II. The further along the testing route they proceed the more added value they have and that this could be applied to SNG. Clearly this was before COVID came about and the AZN deal was alive but demonstrates RM’s knowledge and I think like ability. Interesting pie chart of shareholders too. Griffiths, Lansdowne & Woodford all distressed sellers. Over half the shares in existence, at the time, were right there. Also pleased to see that Southampton University hospital hold 4%. Good to know they will benefit from any success too. All been leading to the next few months. Fingers crossed.:).
https://www.sharesmagazine.co.uk/video/richard-marsden-ceo-of-synairgen-sng
Nobby on ADVFN did say that there are a lot of end points in the COPD trial and could take longer than expected to complete the analysis. He also said that in his opinion they would not be able to retain the data for more than a couple days before release.
I want to believe however that RM has already had some sort of 'top level' readout - hence the interview last week and his apparent new found excitement for the hospital trial result.
From 26th May RNS:
"The Company has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to conduct an unplanned interim analysis on the grounds that data from the 109 COPD patients with confirmed viral infection generates useful safety, biomarker and potentially efficacy data to support ongoing trials of SNG001 in COVID-19 patients."
It's not the full COPD results, it's an "interim analysis... to support ongoing trials of SNG001 in COVID-19 patients"
I very much doubt a company would release supporting data before releasing results.
Agree yes, they have left the door open for the COPD interim analysis results to support either, and, or the SNG001 hospital & at home trials. This is the reason the timeline is left open as "summer".